177 Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis

Clin Nucl Med. 2024 Dec 1;49(12):e668-e669. doi: 10.1097/RLU.0000000000005503. Epub 2024 Oct 14.

Abstract

Patients with metastatic castration-resistant prostate cancer usually have lymph nodes and bone metastasis. We present a rare case of a 51-year-old patient with metastatic castration-resistant prostate cancer who complained of left truncated sciatica and diffuse bone pain and who was referred for 177 Lu-prostate-specific membrane antigen (PSMA) screening. Pretreatment 68 Ga-PSMA showed left sciatic nerve and multiple bone uptake. Patient underwent stereotactic radiotherapy on the sciatic nerve metastasis (30 Gy in 6 fractions of 5 Gy) before 7.4 GBq of 177 Lu-PSMA infusions. Left truncated sciatica disappeared after stereotactic radiotherapy. No additional toxicity was added to the sciatic nerve from 177 Lu-PSMA after stereotactic radiotherapy.

Publication types

  • Case Reports

MeSH terms

  • Dipeptides / therapeutic use
  • Heterocyclic Compounds, 1-Ring* / therapeutic use
  • Humans
  • Ligands
  • Lutetium*
  • Male
  • Middle Aged
  • Prostate-Specific Antigen
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy
  • Radioisotopes / therapeutic use
  • Sciatic Nerve* / diagnostic imaging

Substances

  • Lutetium
  • Heterocyclic Compounds, 1-Ring
  • Dipeptides
  • Ligands
  • PSMA-617
  • Lutetium-177
  • Pluvicto
  • Radioisotopes
  • Prostate-Specific Antigen